Advances in the treatment of superficial fungal infections: Focus on onychomycosis and dry tinea pedis

Journal of the American Osteopathic Association

Volumn 97, Issue 6, 1997, Pages 339-346

  Del Rosso, James Q ^a,b  

^a Medical Center Clinic Pensacola   (United States)

^b Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

Antifungal therapy; Onychomycosis; Trichophyton rubrum

Indexed keywords

ANTIFUNGAL AGENT;

DERMATOMYCOSIS; HUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; TINEA PEDIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; ONYCHOMYCOSIS; PROGNOSIS; TINEA PEDIS; TREATMENT OUTCOME;

EID: 0031156854     PISSN: 00986151     EISSN: None     Source Type: Journal    
DOI: 10.7556/jaoa.1997.97.6.339     Document Type: Article

References (48)

1. Lachapeile JM, De Doncker P, Tennstedt D, et al: Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: An interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. Dermatology 1992;184:45-50.
2. Van Hecke E, Van Cutsem J: Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea pedis and tinea manuum. Mycoses 1988;31:641-649.
3. Greer DL: Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995;34:521-524.
4. Cohen JL, Scher RK, Pappert AS: The nail and fungus infections, in Elewski BE (ed): Topics in Clinical Dermatology: Cutaneous Fungal Infectons. New York, NY, Igaku-Shoin, 1992, pp 106-123.
5. Elewski BE: Clinical pearl: Diagnosis of onychomycosis. J Am Acad Dermatol 1995;32:500-501.
6. Barranco V: Proceedings and transactions. Int J Dermatol 1995;34:284-289.
7. Crissey JT, Lang H, Parish LC: Manual of Medical Mycology. Oxford, UK, Blackwell Science, 1995, pp 19-35, 57-67, 74-77.
8. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part I. J Am Acad Dermatol 1994;30:677-698.
9. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part II. J Am Acad Dermatol 1994;30:911-933.
10. Shear NH, Gupta AK: Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995;131:937-942.
11. Meinhof W: Kinetics and spectrum of activity of oral antifungals: The therapeutic implications. J Am Acad Dermatol 1993;29(Suppl):S37-S41.
12. Cauwenbergh G, Degreef H, Heykants J, et al: Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18(2):263-268.
13. Willemsen M, De Doncker P, Willems J, et al: Post treatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992;6(5):731-735.
14. De Doncker P, Decroix J, Pierard GE, et al: Antifungal pulse therapy for onychomycosisa - pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.
15. Arenas R, Dominguez-Cherit J, Fernandez LMA: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-143.
16. Del Rosso J: Itraconazole: Worldwide experience. Presented at the Annual Midyear Convention of the American Academy of Dermatology; July 1996, Orlando, Fla.
17. Decroix J: Tinea pedis (moccasin-type) treated with itraconazole. Int J Dermatol 1995;34:122-124.
18. Gupta AK, De Doncker P, Heremans A, et al: Itraconazole in tinea pedis: A dose of 400 mg/day for 1 week is more effective than 100 mg/day for 30 days or 200 mg/day for 15 days (Poster). Presented at the Fourth Annual International Summit on Cutaneous Antifungal Therapy, May 1996, Vancouver, BC, Canada.
19. Del Rosso JQ: The appropriateness of liver function test monitoring to determine the effect of oral antifungal medication on hepatic function (Poster). Presented at the Fourth Annual International Summit on Cutaneous Antifungal Therapy, May 1996, Vancouver, BC, Canada.
20. Hay RJ: Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(Suppl):S50-S54.
21. Elewski B, Hay RJ: International summit on cutaneous antifungal therapy. J Am Acad Dermatol 1995;33(pt 1):816-822.
22. Data on file. Janssen Pharmaceutica, Titusville, NJ.
23. Kuokkanen K, Alava S: Fluconazole in the treatment of onychomycosis caused by dermatophytes. Journal of Dermatologic Treatment 1992;3:115-117.
24. Montero-Gei F, Perera A: Therapy with fluconazole for tinea corporis, tinea cruris and tinea pedis. Clin Infect Dis 1992;14(Suppl 1):S77-S81.
25. Del Rosso JQ: Treatment of onychomycosis. Presented at Nail Fungal Infections CME Symposium, February 1996, Orlando, Fla.
26. Haneke E: Pharmacokinetic evaluation of fluconazole in plasma, epidermis and blister fluid. Int J Dermatol 1992;31 (Suppl 2):3-5.
27. Wildfeuer A, Faergemann J, Laufen H, et al: Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994;37:127-130.
28. Faergemann J, Laufen H: Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993;18:102-106.
29. Gearhart MO: Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994;28:1177-1181.
30. Hansten P, Horn J: Drug interactions and updates. Vancouver, Wash, Applied Therapies, Inc, 1996.
31. Grant SM, Clissold SP: Fluconazole - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
32. Balfour JA, Faulds D: Terbinafine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-284.
33. Villars VV, Jones TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992;126(Suppl 39):61-69.
34. 34: Finlay AY: Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992;126(Suppl):28-32.
35. Shatz F, Brautigarn M, Dobrowolski E, et al: Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20:377-383.
36. Tosti A, Piraccini BM, Stinchi C, et al: Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996:595-600.
37. Del Rosso JQ, Gupta AK: Oral antifungal agents: Recognition and management of adverse reactions. Today's Therapeutic Trends 1997 (in press).
38. Canadian Adverse Drug Reaction Monitoring Program. Hepatobiliary reactions with terbinafine hydrochloride. 1996;154:62-63.
39. van't Wout JW, Herrmann WA, de Vries RA, et al: Terbinafine-associated hepatic injury. J Hepatol 1994;21:115-117.
40. Data on file. Sandoz Pharmaceutical, East Hanover, NJ.
41. Lowe G, Green C, Jennings P: Hepatitis associated with terbinafine treatment. Br Med J 1993;306:248.
42. Rzany B, Mockenhaupt M, Gehring W, et al: Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994;30:509.
43. Carstens J, Wendelboe P, Sogaard H, et al: Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol 1994;74:391-392.
44. Kovacs M, Alshammaris, Guenther L, Bourcier M: Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994; 31:806.
45. Gupta AK, Gonder JR, Shear NH, et al: The development of green vision in association with terbinafine therapy Arch Dermatol 1996;132:845-846.
46. Fleckman P: Basic science of the nail unit, in Scher RK, Daniel CR III: Nails: Therapy, Diagnosis. Surgery, Philadelphia, Pa, WB Saunders, 1990, pp 36-51.
47. Update on New Therapies and Management of Onychomycosis. Third Annual International Summit on Cutaneous Antifungal Therapy. August 24-27, 1995, New York, NY.
48. Cohen PR, Scher RK: Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 1994;31(Suppl):S74-S77.